First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).

2564 Background: SAR260301 (SAR) is a potent (IC50 52 nM) PI3Kb inhibitor selectively inhibiting the PI3K pathway in PTEN-null models. This phase I Sanofi sponsored study was initiated to evaluate ...